Australia markets open in 8 hours 5 minutes

Recce Pharmaceuticals Ltd (RCE.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.5500+0.0550 (+11.11%)
At close: 04:10PM AEST

Recce Pharmaceuticals Ltd

Level 23, 180 George Street
Salesforce Tower
Sydney, NSW 2000
Australia
61 2 9256 2505
https://www.recce.com.au

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

NameTitlePayExercisedYear born
Dr. John K. A. Prendergast Ph.D.Executive Chairman of the Board369.85kN/A1954
Mr. James Hamilton-Bray Graham GAICDCEO, MD & Executive Director774.73kN/AN/A
Ms. Michele Keryn Diliza BA (Journ), BSc (Med Sci)Chief Scientific Director & Executive Director539.34kN/AN/A
Dr. Justin WardPrincipal Quality Chemist & Executive Director306.76kN/AN/A
Mr. Arthur KollarasPrincipal Engineer & Head of Manufacturing319.12kN/AN/A
Dr. Alan W. Dunton B.Sc., M.D.Chief Medical Advisor & Independent Non Executive Director72.5kN/A1954
Mr. Justin ReynoldsChief Financial OfficerN/AN/AN/A
Mr. Daniel Astudillo B.A., B.Com., M.B.A.Head of MarketingN/AN/AN/A
Ms. Maggie NiewidokCompany SecretaryN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Recce Pharmaceuticals Ltd, a biotechnology company, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, the company engages in R327 Intravenous which provides serious/life-threatening bacterial infections, including sepsis which is in the phase 1 trial; urinary tract infections, including urosepsis; rapid infusions sepsis in the phase 2 trial; and R327 Topical offers wound infections, including infected burns; and diabetic foot ulcer infections in Phase 2 trails. Further, the company operates various pre-clinical programs, such as Mycobacterium abscessus which is in phase 1 clinical trial; bacterial sinusitis; and additional TBA. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Corporate governance

Recce Pharmaceuticals Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.